Sun Pharmaceuticals Industries (NSE:SUNPHARMA) Cyclically Adjusted Revenue per Share: ₹ (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SUNPHARMA Sun Pharmaceuticals Industries Ltd NSE:SUNPHARMA
92 GF Score
Price ₹1,837.30
GF Value ₹1,973.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Sun Pharmaceuticals Industries Cyclically Adjusted Revenue per Share?

Sun Pharmaceuticals Industries NSE:SUNPHARMA -1.61% 92 Cyclically Adjusted Revenue per Share is ₹ as of Jun. 2026. GuruFocus rates NSE:SUNPHARMA with a GF Score™ of 92/100 and a GF Value™ of ₹1,973.62 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sun Pharmaceuticals Industries's adjusted revenue per share for the three months ended in Jun. 2026 was ₹63.767. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Sun Pharmaceuticals Industries's average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sun Pharmaceuticals Industries was 10.70% per year. The lowest was 6.60% per year. And the median was 8.50% per year.

As of today (2026-09-21), Sun Pharmaceuticals Industries's current stock price is ₹1837.30. Sun Pharmaceuticals Industries's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was . Sun Pharmaceuticals Industries's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sun Pharmaceuticals Industries was 10.86. The lowest was 2.75. And the median was 6.25.


Sun Pharmaceuticals Industries  (NSE:SUNPHARMA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sun Pharmaceuticals Industries was 10.86. The lowest was 2.75. And the median was 6.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sun Pharmaceuticals Industries Cyclically Adjusted Revenue per Share Related Terms


Sun Pharmaceuticals Industries Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sun Pharmaceuticals Industries's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharmaceuticals Industries Cyclically Adjusted Revenue per Share Chart

Sun Pharmaceuticals Industries Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sun Pharmaceuticals Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NSE:SUNPHARMA vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharmaceuticals Industries's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharmaceuticals Industries Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharmaceuticals Industries's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sun Pharmaceuticals Industries's Cyclically Adjusted PS Ratio falls into.


NSE:SUNPHARMA
92GF Score
Sun Pharmaceuticals Industries Ltd NSE:SUNPHARMA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharmaceuticals Industries Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sun Pharmaceuticals Industries's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=63.767/167.3573*167.3573
=63.767

Current CPI (Jun. 2026) = 167.3573.

Sun Pharmaceuticals Industries Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 34.321 105.961 54.207
201612 32.024 105.196 50.947
201703 29.746 105.196 47.323
201706 25.878 107.109 40.434
201709 27.718 109.021 42.550
201712 27.730 109.404 42.419
201803 29.079 109.786 44.328
201806 30.109 111.317 45.267
201809 28.915 115.142 42.028
201812 32.260 115.142 46.890
201903 29.858 118.202 42.275
201906 34.903 120.880 48.323
201909 33.857 123.175 46.001
201912 33.988 126.235 45.060
202003 34.113 124.705 45.780
202006 31.614 127.000 41.660
202009 35.648 130.118 45.850
202012 36.830 130.889 47.092
202103 35.522 131.771 45.115
202106 40.506 134.084 50.558
202109 40.119 135.847 49.425
202112 41.107 138.161 49.794
202203 39.372 138.822 47.465
202206 44.853 142.347 52.734
202209 45.647 144.661 52.809
202212 46.850 145.763 53.791
202303 45.557 146.865 51.914
202306 49.767 150.280 55.422
202309 50.816 151.492 56.138
202312 51.601 152.924 56.471
202403 49.943 153.035 54.617
202406 52.734 155.789 56.650
202409 55.396 157.882 58.721
202412 56.997 158.323 60.249
202503 54.010 157.552 57.371
202506 57.730 159.755 60.477
202509 60.343 162.289 62.227
202512 64.687 163.281 66.302
202603 60.899 164.272 62.043
202606 63.767 167.357 63.767

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹ mean?
Sun Pharmaceuticals Industries (NSE:SUNPHARMA) has a Cyclically Adjusted Revenue per Share of ₹ as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sun Pharmaceuticals Industries and its competitors.
Is Sun Pharmaceuticals Industries' Cyclically Adjusted Revenue per Share too high?
Sun Pharmaceuticals Industries' current Cyclically Adjusted Revenue per Share is ₹. Overall, Sun Pharmaceuticals Industries has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharmaceuticals Industries' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Sun Pharmaceuticals Industries' Cyclically Adjusted Revenue per Share of ₹ can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sun Pharmaceuticals Industries and its competitors. Sun Pharmaceuticals Industries's current Cyclically Adjusted Revenue per Share is ₹. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharmaceuticals Industries stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries (NSE:SUNPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,973.62, compared to a current price of ₹1,837.30 — trading 6.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹. Sun Pharmaceuticals Industries' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sun Pharmaceuticals Industries (NSE:SUNPHARMA), the current Cyclically Adjusted Revenue per Share is ₹ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharmaceuticals Industries (NSE:SUNPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharmaceuticals Industries stock appears to be undervalued. The current stock price of ₹1,837.30 is trading 6.9% below its estimated GF Value™ of ₹1,973.62. GuruFocus considers Sun Pharmaceuticals Industries to be Fairly Valued.

Key valuation signals for NSE:SUNPHARMA:

  • Cyclically Adjusted Revenue per Share:
  • GF Value™: ₹1,973.62 vs. price of ₹1,837.30 (6.9% below fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the NSE:SUNPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharmaceuticals Industries Business Description

Other Exchanges 524715:India
Address Western Express Highway, Sun House, Plot No. 201 B/1, Goregaon (East), Mumbai, MH, IND, 400 063
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
92GF Score

Get the complete analysis for NSE:SUNPHARMA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,837.30
Price
₹1,973.62
GF Value